Oppenheimer Asset Management Inc. Has $30.75 Million Stock Holdings in Bristol Myers Squibb Company (NYSE:BMY)

Oppenheimer Asset Management Inc. increased its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 3.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 504,149 shares of the biopharmaceutical company's stock after purchasing an additional 15,934 shares during the quarter. Oppenheimer Asset Management Inc.'s holdings in Bristol Myers Squibb were worth $30,748,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of Bristol Myers Squibb by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 189,944,516 shares of the biopharmaceutical company's stock worth $10,743,262,000 after acquiring an additional 1,373,209 shares in the last quarter. Capital International Investors lifted its holdings in Bristol Myers Squibb by 7.5% in the 4th quarter. Capital International Investors now owns 45,866,624 shares of the biopharmaceutical company's stock worth $2,593,940,000 after purchasing an additional 3,218,865 shares during the last quarter. Geode Capital Management LLC boosted its position in Bristol Myers Squibb by 2.7% during the fourth quarter. Geode Capital Management LLC now owns 44,391,247 shares of the biopharmaceutical company's stock worth $2,505,967,000 after purchasing an additional 1,187,231 shares during the period. Norges Bank acquired a new position in Bristol Myers Squibb during the fourth quarter valued at approximately $1,989,525,000. Finally, Ameriprise Financial Inc. raised its position in shares of Bristol Myers Squibb by 59.9% in the fourth quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock valued at $1,814,341,000 after purchasing an additional 12,011,983 shares during the period. Institutional investors and hedge funds own 76.41% of the company's stock.

Insider Buying and Selling

In related news, EVP Samit Hirawat purchased 4,250 shares of Bristol Myers Squibb stock in a transaction that occurred on Friday, April 25th. The shares were acquired at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the transaction, the executive vice president now directly owns 83,513 shares in the company, valued at approximately $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.09% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. The Goldman Sachs Group reiterated a "neutral" rating and issued a $55.00 target price (down from $67.00) on shares of Bristol Myers Squibb in a research note on Tuesday, April 8th. Argus raised Bristol Myers Squibb to a "hold" rating in a research report on Friday, April 25th. UBS Group cut their price objective on Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research report on Friday, April 11th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $55.00 target price on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. Finally, William Blair reaffirmed a "market perform" rating on shares of Bristol Myers Squibb in a research report on Friday, April 25th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $58.00.

Bristol Myers Squibb Stock Performance

Bristol Myers Squibb stock traded up $0.00 on Thursday, hitting $46.68. The company's stock had a trading volume of 7,321,269 shares, compared to its average volume of 12,897,945. Bristol Myers Squibb Company has a one year low of $39.35 and a one year high of $63.33. The firm has a market cap of $95.01 billion, a P/E ratio of 17.48, a price-to-earnings-growth ratio of 1.38 and a beta of 0.38. The company has a quick ratio of 1.17, a current ratio of 1.28 and a debt-to-equity ratio of 2.65. The company has a fifty day moving average price of $47.96 and a 200-day moving average price of $54.02.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The firm had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. During the same period in the prior year, the company posted ($4.40) earnings per share. The business's revenue for the quarter was down 5.6% compared to the same quarter last year. On average, equities analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be issued a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 5.31%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's payout ratio is currently 92.88%.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.